Current immunotherapeutic targets in gliomas


Journal Article (Chapter)

The prospect for high-grade astrocytic tumor patients continues to be dismal, evenwith advances in surgery, radiotherapy, and chemotherapy. There is a need for thedevelopment of novel therapies that would eliminate the heterogeneous and diffuseastrocytic tumor cells.Innovative therapeutic approaches for the treatment of central nervous systemneoplasia, such as antibody-mediated immunotherapeutics, cellular immunotherapeutics,and oncolytic viruses targeting tumor-associated antigens, have emerged during the pastfew years.Herein we review several of the glioma-associated antigens and the current status ofimmunotherapeutics and oncolytic viruses targeting these antigens. © 2013 Nova Science Publishers, Inc. All rights reserved.

Duke Authors

Cited Authors

  • Chandramohan, V; Mitchell, DA; Gromeier, M; Sampson, JH; Bigner, DD

Published Date

  • May 1, 2013

Start / End Page

  • 287 - 305

Citation Source

  • Scopus